Board of Directors
Theodore H. Stanley, M.D., Chairman and Founder
Theodore H. Stanley, M.D. is a co-founder and has been our non-executive Chairman since inception. Dr. Stanley is a Professor of Anesthesiology at the University of Utah, where he has been employed for the past 35 years. In 1985, he co-founded Anesta, a drug delivery company, which was acquired by Cephalon, Inc. in 2000. Dr. Stanley is also an executive officer of the National Academy of Perioperative Echocardiography, NeuroAdjuvants, Inc. and the Stanley Research Foundation. Dr. Stanley received an A.B. in 1961 from Columbia College and his medical degree from the Columbia University Medical School.
Larry D. Rigby, Vice-Chairman and Founder
Larry D. Rigby was our Chief Executive Officer from inception to January 2006. He has been a member of our board of directors since inception and is currently Vice Chairman. Prior to co-founding ZARS, Mr. Rigby was President and founder of MicroJect, a medical device company, which was acquired in 1998 by Sorenson Development. In August 1986 he founded and became Chief Executive Officer of CardioPulmonics, a medical device company. From August 1985 to June 1995 he was Chairman and founder of Alton Dean Medical, which was acquired by Mallinckrodt Medical in June 1995. From August 1982 to August 1985, he was President of Martin U.S.A. Mr. Rigby started his career with Sorenson Research Company in August 1975 where he was Vice President of Sales and Marketing. Currently, he is Chairman and Chief Executive Officer of Larada Sciences and Chairman of Exeven Therapeutics. Mr. Rigby has a B.A. from Idaho State University and an M.A. from the University of Kansas.
Robert Lippert, President and CEO
Robert Lippert has been our President and Chief Executive Officer since January 2006 and a director since July 2006. Previously, Mr. Lippert was our Chief Operating Officer since joining ZARS in January 2004. Prior to joining ZARS, Mr. Lippert was President and Chief Executive Officer at ProCertus BioPharm, Inc., an oncology pharmaceutical company, from June 2001 to December 2003, and has been a member of its board of directors from June 1998 to present. Prior to joining ProCertus, Mr. Lippert was Senior Vice President of Exponential Biotherapies, Inc., a biopharmaceutical company, from February 2000 to February 2003. Additionally, Mr. Lippert also held Senior Vice President and Vice President positions at Celltech Medeva plc, a pharmaceutical company in marketing, sales, and business development. Mr. Lippert also held several middle management positions at Ohmeda Pharmaceutical Products, a pharmaceutical company acquired by Baxter Pharmaceuticals, where he worked in the finance, marketing, and business development departments. Mr. Lippert received a B.A. in animal biology and a B.B.A. in finance from the University of Wisconsin and an M.B.A. from Marquette University.
Richard H. Leazer, Director
Richard H. Leazer has been one of our directors since February 2000. Mr. Leazer has been a principal in Wisconsin Investment Partners, L.L.C. since January 2000. Mr. Leazer was previously a Managing Director of the Wisconsin Alumni Research Foundation, a not-for-profit corporation supporting research at the University of Wisconsin, where he served from February 1992 to December 1999. Prior to that, he was President of Ohmeda Pharmaceutical Products, a pharmaceutical company acquired by Baxter Pharmaceuticals, from August 1988 through October 1992. From October 1981 through July 1988, he was President of Anaquest, an anesthesia pharmaceutical company and a division of BOC Healthcare. He received a B.S. in business administration from the University of Iowa and an M.B.A. from the Drexel Institute of Technology.
Steve T. Jurvetson, Director, Managing Director of Draper Fisher Jurvetson
Steve T. Jurvetson has been one of our directors since August 2004. He has been a managing director of Draper Fisher Jurvetson, a venture capital fund, since January 1997. Previously, Mr. Jurvetson was a part-time research and development engineer at Hewlett-Packard from June 1987 to September 1989 and a consultant with Bain & Company from June 1990 to September 1993. Mr. Jurvetson is currently Co-Chair of the NanoBusiness Alliance. Mr. Jurvetson has received a B.S. and M.S. in electrical engineering from Stanford University and an M.B.A. from the Stanford Business School.
F. Lynn DeBry, Director
F. Lynn DeBry has been one of our directors since July 2006. Mr. DeBry is a retired partner of KPMG LLP where he worked in the New York, Sao Paulo, Brazil and Salt Lake offices from 1969 to 2000. From February 2001 to June 2002, Mr DeBry served as Chief Financial Officer of Cirque Corporation, a computer peripherals company. He has served on the board of directors of First USA Financial Services, Inc., Utah Technologies Association, Wayne Brown Institute and Utah Boys' Ranch. Mr. DeBry has a B.S. in accounting from the University of Utah.
Bill Humphries, Director
William “Bill” Humphries is president of Dermatology for Stiefel, a GSK company. Stiefel, acquired by GlaxoSmithKline in July 2009, is a specialty business unit within GSK. As president of dermatology, Humphries is responsible for the overall financial performance of Stiefel as well as for setting global marketing and sales strategies. He also provides oversight for Glades Pharmaceuticals, a wholly-owned subsidiary of Stiefel Laboratories.
Prior to the acquisition by GSK, Humphries served in various positions at Stiefel including president and chief commercial officer. His accomplishments in these roles included orchestrating the creation of an integrated global commercial team and the successful acquisitions of Connetics Corporation, ABR Invent & ABR Development, and Barrier Therapeutics. He also was instrumental in the 2007 private equity minority investment agreement between Stiefel Laboratories and The Blackstone Group.
Before joining Stiefel Laboratories in 2003, Humphries was vice president of Sales and Marketing, Skin Care, for Allergan, Inc., where he oversaw marketing and sales management, training, operations and business development.
Humphries is a 21-year veteran of the pharmaceutical industry, with 20 of those years focused on the specialty of dermatology. Throughout his career, he has amassed experience in sales, sales training, sales operations, marketing, global marketing and corporate development. In addition, Humphries has held P&L responsibility both at Allergan and Stiefel Laboratories.
Humphries is a graduate of Bucknell University, where he majored in management and economics. He also earned an MBA from Pepperdine University. He and his family live in Raleigh, North Carolina.